NCT06439888View on ClinicalTrials.gov

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

January 31, 2027

Conditions
Oligometastatic DiseaseSolid Tumor, Adult
Interventions
DRUG

all-trans retinoic acid

per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles

RADIATION

Stereotactic Body Radiation Therapy

Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated

Trial Locations (2)

69000

NOT_YET_RECRUITING

Centre Léon Bérard, Lyon

94800

RECRUITING

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER